METHOD AND COMPOSITION FOR ALTERING A T CELL MEDIATED PATHOLOGY

摘要

The present invention provides a method for altering a T cell mediated pathology in a patient. This method comprises administering a composition comprising at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the V.alpha. or V.beta. region of a T CR from particular T cells from a patient having a T cell mediated pathology, a nd an immunoglobulin constant region. The genes encoding V.alpha. and/or V.beta.~~~.epsilon..gamma.~~~.sigma.~.alpha.~.delta.~~~.epsilon.~.gamma..eps ilo n.~.epsilon..sigma.~.epsilon.~~~.delta.~~.gamma.~~.mu..mu..theta.~~.gamma..l amb da.~.beta..theta..lambda.~~~~~~.sigma.~.alpha.~~~~.epsilon..gamma.~~~.sigma. ~.a lpha.~.epsilon.~~.sigma.~.lambda..alpha.~.epsilon..delta.~.alpha.~.delta.~~~ .si gma..epsilon.~~.epsilon..delta.~~~~~~.alpha.~~.epsilon.~.pi.~.epsilon..sigma ..s igma.~~~~.omega..epsilon.~~~~~~~~.epsilon.~~~~.mu..epsilon.~~~~.pi.~~~.epsil on. ~~.sigma.~.alpha.~.epsilon.~.pi.~~.delta..theta.~.epsilon..delta.~.beta.~~~~ ~~~ .delta..theta.~~~.gamma.~~~.epsilon.~.epsilon.~.pi.~.epsilon..sigma..sigma.~ ~~~ .omega..epsilon.~~~~.sigma.~~~~~~~~.sigma..epsilon.~~~~.epsilon..lambda..lam bda .~.lambda.~~.epsilon..sigma.~~~~.epsilon.~~~~.mu..epsilon.~~~~.pi.~~~.epsilo n.~ ~.sigma.~.alpha.~.epsilon.~.pi..theta.~~~~.epsilon..delta.~.theta..sigma.~~. gam ma.~.alpha.~~~.beta.~.delta.~~.alpha.~~~~~~~~~~.lambda..theta..mu.~.sigma.~~ .al pha.~.delta.~~~.epsilon.~~~~.epsilon..mu.~~.alpha..lambda..lambda.~~~~~~.the ta. .gamma..alpha.~.epsilon..delta.~~~~.alpha.~~~.mu..mu..theta.~~.gamma..epsilo n.~ ~~~~.alpha.~~~.epsilon.~~~~.epsilon.~~~.lambda..epsilon.~.lambda.~.mu..pi..e psi lon.~~~.epsilon..mu.~~~.alpha.~~~~~~~~. Since the conjugates comprises chimeric proteins made specifically from particular T cells from a patient having T cell mediated pathology, when it is administered to such a patient, with or without a cytokine, such as granulocyte-macrophage-CSF, or a chemokine, it can induce immune responses to alter such a T cell mediated pathology.